In the claims:

Please cancel claims 2-10, without prejudice or disclaimer. Please retain claim 1 and add claims 11-34 to recite as follows:

Claim 1 (original). A recombinant MVA containing and capable of expressing one or more DNA sequences encoding dengue virus antigens.

Claims 2-10 (cancelled).

Claim 11 (new). A composition comprising a first and second component, wherein the first component is a vector comprising a DNA sequence encoding a Dengue virus antigen, wherein said DNA sequence is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, and a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase.

Claim 12 (new). The composition of Claim 11, wherein the vector of the first component is a plasmid.

Claim 13 (new). The composition of Claim 11, wherein the DNA sequence encoding Dengue virus antigen is selected from the group consisting of DNA sequences encoding preM, E and NS1 antigens.

Claim 14 (new). The composition according to Claim 11, wherein the DNA sequence encoding the T7 RNA polymerase is inserted at a site of a naturally occurring deletion with the MVA genome.

Claim 15 (new). A pharmaceutical composition comprising the composition of Claim 11 and a pharmaceutically acceptable carrier or diluent.

Claim 16 (new). A cell comprising the composition of Claim 11.

Claim 17 (new). A cell comprising the composition of Claim 15.

Claim 18 (new). A pharmaceutical composition comprising the cell of Claim 16 and a pharmaceutically acceptable carrier or diluent.

Claim 19 (new). A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the composition of any one of Claims 11 to 15 or 18.

Claim 20 (new). The method according to Claim 19, wherein the animal is a human.

Claim 21 (new). A recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding a Dengue virus antigen inserted at the site of one or more naturally occurring deletions within the MVA virus genome, and wherein said DNA sequence is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, and a DNA sequence encoding a Dengue virus serotype 4 antigen.

Claim 22 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 21, wherein the DNA sequence encodes a Dengue virus serotype 2 antigen.

Claim 23 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 21, wherein the DNA sequence is inserted at deletion site II within the MVA virus genome.

Claim 24 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 21 or 23, wherein the DNA sequence encodes a Dengue virus preM antigen.

Claim 25 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 24, wherein the DNA sequence encoding the pre-M antigen is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.

Claim 26 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 21, wherein said DNA sequence encodes a Dengue virus NS-1 antigen.

Claim 27 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 21, wherein said DNA sequence is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype 4 NS-1 antigen.

Claim 28 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 24, further comprising a second DNA sequence selected from the group consisting of a Dengue virus serotype 1 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 2 NS-1 antigen, a DNA sequence encoding a Dengue virus serotype 3 NS-1 antigen, and a DNA sequence encoding a Dengue virus serotype 4 NS-1 antigen and wherein said second DNA sequence is inserted at the site of one or more naturally occurring deletions within the MVA virus genome.

Claim 29 (new). The recombinant Modified Vaccinia Ankara (MVA) virus of Claim 28, wherein the second DNA sequence is inserted at deletion site II within the MVA virus genome.

Claim 30 (new). A composition comprising the recombinant Vaccinia Ankara (MVA) virus of Claims 21 or 28 and a pharmaceutically acceptable carrier or diluent.

Claim 31 (new). A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the recombinant Modified Vaccinia Ankara (MVA) virus of Claims 21 or 28.

Claim 32 (new). The method according to Claim 31, wherein the animal is a human.

Claim 33 (new). A process for preparing a recombinant Modified Vaccinia Ankara virus (MVA) comprising inserting the composition of Claim 11 into a suitable cell and propagating the cell under conditions that favor recombination between the first and second components of the compositions.

Claim 34 (new). The process of Claim 33, further comprising isolating the recombinant Modified Vaccinia Ankara (MVA) virus from the cell.